Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
eribulin
metastatic breast cancer
multicentre
prospective
real world
third line
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
03
2019
accepted:
15
11
2019
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
7
1
2020
Statut:
epublish
Résumé
In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the median age was 58 years (range 29-79), with 69% of patients under 65. The median cycles of eribulin were 5.5 (range 1-26). The most common adverse event was neutropenia (9.3%, 3 cases of grade 3, 4 of grade 4); only 1 case of QT prolongation was reported. Eribulin was effective in controlling metastatic disease in all sites, and it achieved the highest ORR in brain (16%) and liver (14.9%). Median OS was 31.8 months (95% CI 27.9-34.4) and median PFS 5.5 months (95% CI 4.2-6.6). PFS was 5.2 months (95% CI 2.8-8.4) in patients with triple-negative subtype. Median PFS was longer in patients over 65 years (6.1 months, 95% CI 4.4-8.3). In patients who had visceral metastases PFS was 5.5 months (95% CI 95% 3.5-6.6) and OS 33.9 months (95% CI 29.8-40.8). Eribulin as third-line treatment shows an acceptable safety profile and a substantial antitumour activity in the treatment of MBC, even in elderly patients and in those with visceral disease.
Sections du résumé
BACKGROUND
BACKGROUND
In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC).
METHODS
METHODS
In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS).
RESULTS
RESULTS
From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the median age was 58 years (range 29-79), with 69% of patients under 65. The median cycles of eribulin were 5.5 (range 1-26). The most common adverse event was neutropenia (9.3%, 3 cases of grade 3, 4 of grade 4); only 1 case of QT prolongation was reported. Eribulin was effective in controlling metastatic disease in all sites, and it achieved the highest ORR in brain (16%) and liver (14.9%). Median OS was 31.8 months (95% CI 27.9-34.4) and median PFS 5.5 months (95% CI 4.2-6.6). PFS was 5.2 months (95% CI 2.8-8.4) in patients with triple-negative subtype. Median PFS was longer in patients over 65 years (6.1 months, 95% CI 4.4-8.3). In patients who had visceral metastases PFS was 5.5 months (95% CI 95% 3.5-6.6) and OS 33.9 months (95% CI 29.8-40.8).
CONCLUSIONS
CONCLUSIONS
Eribulin as third-line treatment shows an acceptable safety profile and a substantial antitumour activity in the treatment of MBC, even in elderly patients and in those with visceral disease.
Identifiants
pubmed: 31903098
doi: 10.1177/1758835919895755
pii: 10.1177_1758835919895755
pmc: PMC6923689
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835919895755Informations de copyright
© The Author(s), 2019.
Déclaration de conflit d'intérêts
Conflict of interest statement: The author(s) declare that there are no conflicts of interest.
Références
Springerplus. 2016 Jan 21;5:59
pubmed: 26835238
Future Oncol. 2017 Apr;13(11s):5-10
pubmed: 28481186
Breast Care (Basel). 2013 May;8(2):102-9
pubmed: 24000280
Lancet. 2011 Mar 12;377(9769):914-23
pubmed: 21376385
Breast Cancer Res Treat. 2014 Dec;148(3):553-61
pubmed: 25381136
J Clin Oncol. 2015 Feb 20;33(6):594-601
pubmed: 25605862
Br J Clin Pharmacol. 2013 Sep;76(3):412-24
pubmed: 23601153
Mayo Clin Proc. 2009 Jun;84(6):533-45
pubmed: 19483170
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
BMC Cancer. 2015 Oct 08;15:659
pubmed: 26449988
J Clin Oncol. 2010 Sep 1;28(25):3922-8
pubmed: 20679609
Future Oncol. 2017 May;13(11):971-978
pubmed: 28326833
Biometrics. 1985 Jun;41(2):361-72
pubmed: 4027319
Future Oncol. 2014 Dec;10(15):2417-22
pubmed: 25525850
ESMO Open. 2017 Jun 2;2(2):e000176
pubmed: 28761747
BMC Cancer. 2017 Dec 4;17(1):819
pubmed: 29202787
Cancer Res. 2011 Jan 15;71(2):496-505
pubmed: 21127197
Clin Breast Cancer. 2014 Dec;14(6):405-12
pubmed: 25024001